Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma L. McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone Bigi-Botterill, Tony S. Gibson, Rebecca B. Watson, Yiyang Liu, Christopher J. O'Donnell
Summary: This Review presents the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020. These privileged structures with affinities for biological targets implicated in human diseases and conditions, particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and serve as leads for future drug design.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone Bigi-Botterill, Tony S. Gibson, Yiyang Liu, Christopher J. O'Donnell
Summary: New drugs introduced to the market are privileged structures with affinities for biological targets implicated in human diseases, providing insights into molecular recognition and guiding future drug design.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, Andrew C. Flick, Erick A. Lindsey, Simon Berritt, Daniel W. Carney, Jacob C. DeForest, Hong X. Ding, Sarah J. Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, Yiyang Liu, Subham Mahapatra, Indrawan J. McAlpine, Rebecca B. Watson, Christopher J. O'Donnell
Summary: New drugs introduced to the market each year provide valuable insights into molecular recognition and potential leads for future medicines. This annual review focuses on the process-scale synthetic approaches to 35 newly approved compounds worldwide in 2021, including small molecules and antibody-drug conjugates.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Chemistry, Medicinal
Zhen-Xi Niu, Peng Nie, Piet Herdewijn, Ya-Tao Wang
Summary: This review provides a comprehensive overview of synthetic routes to antiviral agents used in the management of hepatitis, elucidating the mechanisms of action, clinical applications, and potential research directions. It contributes to improved patient outcomes and reduced global disease burden.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Chemistry, Medicinal
Xiao-Jing Li, Peng Nie, Piet Herdewijn, Jian-Gang Sun
Summary: Gastrointestinal cancers are a significant global health burden, and small-molecule drugs have emerged as crucial therapeutic options. This review provides valuable insights into the clinical applications and synthetic methods of clinically approved small-molecule drugs, as well as discussing future prospects.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Public, Environmental & Occupational Health
Jing Luo, Shunlong Ou, Hua Wei, Xiaoli Qin, Rui Peng, Song Wang, Qian Jiang
Summary: This study aimed to assess the value of new cancer drugs approved in China and explore the association between drug price and value. The results showed that not all approved drugs had meaningful value, and there was no significant correlation between drug price and clinical benefit.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Biochemistry & Molecular Biology
Nazar Moshnenko, Alexander Kazantsev, Evgeny Chupakhin, Olga Bakulina, Dmitry Dar'in
Summary: The use of spirocycles in drug discovery and medicinal chemistry has seen significant growth in the past two decades, with 50% of clinically used medicines containing a spirocycle being approved in the 21st century. This review focuses on synthetic routes to such drugs developed in industry and academia, serving as a valuable reference for researchers in the design of new spirocyclic scaffolds or analog syntheses inspired by approved drugs.
Article
Biochemistry & Molecular Biology
Ayazoddin Aunoddin Kazi, B. V. Subba Reddy, L. Ravithej Singh
Summary: Respiratory infections caused by pulmonary inflammation are a leading cause of death worldwide, yet only twenty-seven new drugs have been approved in the past fifty years. This review outlines synthetic approaches and mode of action for these FDA-approved medications used to treat asthma and COPD.
BIOORGANIC & MEDICINAL CHEMISTRY
(2021)
Review
Medicine, General & Internal
Alex M. Ebied, Hesham Elmariah, Rhonda M. Cooper-DeHoff
Summary: According to the FDA, 50 novel drugs were approved in 2021, with a majority being reviewed and approved through an expedited pathway, and over half of them approved for the treatment of rare diseases.
AMERICAN JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Alex M. Ebied, Hesham Elmariah, Rhonda M. Cooper-DeHoff
Summary: In 2022, the FDA approved 37 novel drugs, with 24 (65%) of them being reviewed and approved through an expedited pathway and 20 (54%) approved for rare disease treatment. This article provides a summary of the novel drugs approved by the FDA in 2022.
AMERICAN JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Alex M. Ebied, Hesham Elmariah, Rhonda M. Cooper-DeHoff
Summary: In 2020, the US Food and Drug Administration approved 53 novel drugs, with the majority being reviewed and approved through an expedited review pathway, and over half being approved for the treatment of rare diseases.
AMERICAN JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Stephane Jeanmart, Andrew J. F. Edmunds, Clemens Lamberth, Martin Pouliot, James A. Morris
Summary: This review discusses the synthesis of 33 agrochemicals with ISO names from January 2015 to December 2018, showcasing the wide range of reactions, reagents, and intermediates used to discover and produce the latest active ingredients for the crop protection industry.
BIOORGANIC & MEDICINAL CHEMISTRY
(2021)
Review
Chemistry, Medicinal
Ghulam Shabir, Aamer Saeed, Wajeeha Zahid, Fatima Naseer, Zainab Riaz, Nafeesa Khalil, Mary J. Muneeba, Fernando Albericio
Summary: Fluorine substitution has been extensively explored for improving drug properties, such as increasing biological activity and enhancing stability. Selective substitution of fluorine onto therapeutic or diagnostic drugs can enhance pharmacokinetic and physicochemical properties. The use of fluorine in radiolabeling and PET imaging has also been studied. This review reports on FDA-approved fluorinated drugs and provides examples from various therapeutic and diagnostic drugs.
Article
Biochemistry & Molecular Biology
Carla Rizzo, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi, Antonio Palumbo Piccionello
Summary: The incorporation of fluorine atoms or heterocyclic moieties into drug structures is a common pattern in medicinal chemistry. The combination of these two features is consistently observed in newly synthesized molecular entities with diverse biological activities, as evidenced by the increasing number of Fluorinated heterocyclic compounds approved by the FDA as drugs. This review highlights the biological activity and synthetic aspects of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Chemistry, Medicinal
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang, Bo Jing
Summary: A high incidence of cancer has led to the development of fifty-six new small-molecule anticancer drugs from 2015 to 2020, categorized into ten groups based on their antitumor targets. Among these drugs, PTK inhibitors have played a key role in changing the paradigm of cancer treatment, with lower toxicity and higher potency.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Biochemistry & Molecular Biology
Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K. -C. Liu, Sarah J. Fink, Andrew C. Flick, Christopher J. O'Donnell
BIOORGANIC & MEDICINAL CHEMISTRY
(2015)
Review
Biochemistry & Molecular Biology
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K. -C. Liu, Sarah J. Fink, Christopher J. O'Donnell
BIOORGANIC & MEDICINAL CHEMISTRY
(2016)
Article
Chemistry, Medicinal
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K. -C. Liu, Sarah J. Fink, Christopher J. O'Donnell
JOURNAL OF MEDICINAL CHEMISTRY
(2017)
Article
Chemistry, Medicinal
Jose H. Pereira, Chutima Petchprayoon, Alexander C. Hoepker, Nigel W. Moriarty, Sarah J. Fink, Giuseppe Cecere, Ian Paterson, Paul D. Adams, Gerard Marriott
Article
Chemistry, Organic
Thomas E. Smith, Sarah J. Fink, Zebulon G. Levine, Kerani A. McClelland, Adrian A. Zackheim, Mary E. Daub
Article
Chemistry, Organic
Ian Paterson, Sarah J. Fink, Lydia Y. W. Lee, Stephen J. Atkinson, Simon B. Blakey
Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Christopher J. O'Donnell
JOURNAL OF MEDICINAL CHEMISTRY
(2019)
Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, Christopher J. O'Donnell
JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone Bigi-Botterill, Tony S. Gibson, Yiyang Liu, Christopher J. O'Donnell
Summary: New drugs introduced to the market are privileged structures with affinities for biological targets implicated in human diseases, providing insights into molecular recognition and guiding future drug design.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma L. McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone Bigi-Botterill, Tony S. Gibson, Rebecca B. Watson, Yiyang Liu, Christopher J. O'Donnell
Summary: This Review presents the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020. These privileged structures with affinities for biological targets implicated in human diseases and conditions, particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and serve as leads for future drug design.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Chemistry, Medicinal
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, Andrew C. Flick, Erick A. Lindsey, Simon Berritt, Daniel W. Carney, Jacob C. DeForest, Hong X. Ding, Sarah J. Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, Yiyang Liu, Subham Mahapatra, Indrawan J. McAlpine, Rebecca B. Watson, Christopher J. O'Donnell
Summary: New drugs introduced to the market each year provide valuable insights into molecular recognition and potential leads for future medicines. This annual review focuses on the process-scale synthetic approaches to 35 newly approved compounds worldwide in 2021, including small molecules and antibody-drug conjugates.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
